



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Short Communication

Heat inactivation of the severe acute respiratory syndrome coronavirus 2

Christophe Batéjat^a, Quentin Grassin^a, Jean-Claude Manuguerra^a, India Leclercq^{a,b,*}^aInstitut Pasteur, Unité Environnement et Risques Infectieux, Cellule d'Intervention Biologique d'Urgence (CIBU), 28 rue du Dr. Roux, Paris, France^bUniversité de Paris, Cellule Pasteur, 28 rue du Dr. Roux F-75015 Paris, France

ARTICLE INFO

Article history:

Received 2 July 2020

Received in revised form 18 November 2020

Accepted 16 December 2020

Keywords:

Heat

Inactivation

SARS-CoV-2

Covid-19

ABSTRACT

Cell culture medium, nasopharyngeal and sera samples spiked with SARS-CoV-2 were subjected to heat inactivation for various periods of time, ranging from 30 s to 60 min. Our results showed that SARS-CoV-2 could be inactivated in less than 30 min, 15 min, and 3 min at 56 °C, 65 °C, and 95 °C, respectively. These data could help laboratory workers to improve their protocols by handling the virus in biosafety conditions.

© 2021 Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

In December 2019, a new coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan City, Hubei Province in China and quickly became pandemic, spreading to almost all countries in about 2 months. This highly contagious virus has already caused a great number of infections and deaths, and the scientific community is facing new challenges to combat the ongoing outbreak. As no specific therapeutics and vaccines are available for disease control, lockdowns, social distancing, and quick detection of cases are currently the main weapons against the virus. Diagnostic and serological tools help to detect SARS-CoV-2 carriers and immunized recovered patients as soon as possible, and are therefore part of this fighting strategy and necessary to consider a return to normal life. In this context, viral inactivation procedures are urgently needed to allow safe experimental laboratory conditions. Amplification of viral RNA by quantitative RT-PCR is currently the gold standard procedure for diagnosis recommended by the World Health Organization.¹ Viral RNA extraction kits sometimes require an initial lysis step at 70 °C or more for 5 min. Heat inactivation of the virus is also needed for serum treatment before ELISA and serological assays.

Although 56 °C is commonly used for inactivation of enveloped viruses,^{2,3} higher temperatures can be used in some cases.^{4–6} This temperature is also used to eliminate serum complement. In this study, we exposed SARS-CoV-2 to three different inactivation temperatures (56 °C, 65 °C, and 95 °C) for various periods of time and tested its infectivity using the TCID₅₀ method.

* Corresponding author at: Université de Paris, Cellule Pasteur, 28 rue du Dr. Roux F-75015 Paris, France.

E-mail address: india.leclercq@pasteur.fr (I. Leclercq).

A human strain of SARS-CoV-2, isolated from a French patient hospitalized in February 2020 (GISAID accession number: EPI_ISL_437689), was grown on Vero E6 cells for three passages. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM 1X, GIBCO) supplemented with 5% fetal calf serum (FCS) and antibiotics (0.1 units penicillin, 0.1 mg/mL streptomycin, GIBCO) at 37 °C in a humidified 5% CO₂ incubator. The SARS-CoV-2 virus was titrated by the TCID₅₀ method, as described previously,⁷ except that Vero E6 cells were used and examination for cytopathic effect was performed after 5 days. The viral titer was adjusted from 6.5 log₁₀ TCID₅₀/mL to a final titer of 6 log₁₀ TCID₅₀/mL in three different kinds of media, that is, cell culture medium (DMEM 1X), pooled nasopharyngeal samples of several patients tested negative for SARS-CoV-2, and pooled sera from donors collected before the 1st of January 2020 at a time when the virus was not circulating in France.

Diluted samples (500 µL) were submitted in triplicate to various temperatures for different periods of time in a calibrated and verified dry water bath, cooled on ice, and tested for infectivity by the TCID₅₀ method as described above. All experiments were conducted under strict BSL3 conditions.

The mean viral titers obtained for each condition are presented in Tables 1, 2, and 3. Viral inactivation over time is shown in Fig. 1.

At 56 °C, no infectious virus was detected within 30 min in cell culture medium (Fig. 1A) and within 20 min in nasopharyngeal samples and sera (Fig. 1B and 1C). As expected, increasing the temperature had a negative effect on viral infectivity as no infectious virus was detected within 15 min at 65 °C (Fig. 1A and 1B). At 95 °C, 3 min was sufficient to inactivate the virus in nasophary-

Table 1

Log₁₀ TCID₅₀ per mL titers obtained after inactivation of cell culture medium containing 6 log₁₀ TCID₅₀/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log₁₀ TCID₅₀ per ml).

Time (min)	56 °C					65 °C			
	0	15	30	38	60	0	15	30	60
Cell culture medium	6.6	3.23	ND	ND	ND	6.6	ND	ND	ND

Table 2

Log₁₀ TCID₅₀ per mL titers obtained after inactivation of nasopharyngeal samples spiked with 6 log₁₀ TCID₅₀/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log₁₀ TCID₅₀ per ml).

Time (min)	56 °C				65 °C				95 °C			
	0	10	20	30	0	5	10	15	0	0.5	3	6
Nasopharyngeal samples	6.17	2.77	ND	ND	6.57	4.83	ND	ND	6.57	6.23	ND	ND

Table 3

Log₁₀ TCID₅₀ per mL titers obtained after inactivation of human sera spiked with 6 log₁₀ TCID₅₀/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log₁₀ TCID₅₀ per ml).

Time (min)	56 °C					
	0	5	10	15	20	30
Sera	6.2	4.87	2.57	ND	ND	ND




Fig. 1. Viral titers in log₁₀ TCID₅₀/mL obtained after heat inactivation of infected cell culture medium (A), nasopharyngeal samples spiked with SARS-CoV-2 (B), and sera samples from negative donors spiked with SARS-CoV-2 (C). Each condition was performed in triplicate. Each dot represents the mean viral titer and vertical lines represent the standard deviation.

geal samples (Fig. 1B). The high quantity of infectious virus detected after 30 s ($6.23 \log_{10}$ TCID₅₀/mL) was probably due to the time necessary for the media and the tubes to reach 95 °C inside.

To complement our results, viral RNA from each sample, except from nasopharyngeal samples treated at 56 °C, was extracted using a Nucleospin RNA Virus kit (Macherey-Nagel) for quantitative RT-PCR. Primers and probes targeting two regions of the RdRP gene developed by the French National Reference Center for Respiratory Infections Viruses and a LightCycler 480 II instrument were used as previously described.⁸ The E gene was used as a tertiary target for confirmation, following the Charité protocol.⁹ The results showed that the mean genomic RNA copy number ranged between 9.9×10^7 copy genome/5 µL and 5.3×10^9 copy genome/5 µL (data not shown). For each condition, the quantity of viral RNA was very stable over time, suggesting that viral RNA remained intact in virus particles. At 95 °C, the results showed a slight decrease in viral RNA quantity over time with approximately a 2.2-fold increase in the cq value, which could potentially prevent SARS-CoV-2 detection in samples with low viral loads.^{10,11}

These results are similar to our previous results obtained with the Middle East Respiratory Syndrome coronavirus (MERS-CoV),⁵ which belongs to the same genus of viruses. In conclusion, SARS-CoV-2 is relatively sensitive to heat inactivation under our laboratory conditions. These data can help laboratory workers to elaborate and improve their protocols for SARS-CoV-2 experiments, and reinforce our current knowledge on coronavirus survival.^{12,13}

CRediT authorship contribution statement

Christophe Batéjat: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing - review & editing. **Quentin Grassin:** Investigation. **Jean-Claude Manuguerra:** Resources, Writing - review & editing. **India Leclercq:** Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. WHO-COVID-19-lab_testing-2020.1-eng.pdf. Accessed April 28, 2020. https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf
2. Cutts T, Grolla A, Jones S, Cook BWM, Qiu X, Theriault SS. Inactivation of Zaire ebolavirus variant Makona in human serum samples analyzed by enzyme-linked immunosorbent assay. *J Infect Dis.* 2016;214(suppl 3):S218–S221. <https://doi.org/10.1093/infdis/jiw289>.
3. Park SL, Huang Y-JS, Hsu W-W, Hettenbach SM, Higgs S, Vanlandingham DL. Virus-specific thermostability and heat inactivation profiles of alphaviruses. *J Virol Methods.* 2016;234:152–155. <https://doi.org/10.1016/j.jviromet.2016.04.004>.
4. Edwards S. Survival and inactivation of classical swine fever virus. *Vet Microbiol.* 2000;73(2):175–181. [https://doi.org/10.1016/S0378-1135\(00\)00143-7](https://doi.org/10.1016/S0378-1135(00)00143-7).
5. Leclercq I, Batéjat C, Burguière AM, Manuguerra J-C. Heat inactivation of the Middle East respiratory syndrome coronavirus. *Influenza Other Respir Viruses.* 2014;8(5):585–586. <https://doi.org/10.1111/irv.12261>.
6. Saluzzo JF, Leguenno B, Van der Groen G. Use of heat inactivated viral haemorrhagic fever antigens in serological assays. *J Virol Methods.* 1988;22(2-3):165–172. [https://doi.org/10.1016/0166-0934\(88\)90099-7](https://doi.org/10.1016/0166-0934(88)90099-7).
7. Dublineau A, Batéjat C, Pinon A, Burguière AM, Leclercq I, Manuguerra J-C. Persistence of the 2009 pandemic influenza A (H1N1) virus in water and on non-porous surface. *PloS One* 2011;6(11):e28043. doi:10.1371/journal.pone.0028043
8. real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf. Accessed April 29, 2020. https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2
9. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance.* 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045
10. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis.* 2020;20(4):411–412. [https://doi.org/10.1016/S1473-3099\(20\)30113-4](https://doi.org/10.1016/S1473-3099(20)30113-4).
11. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature.* 2020;1–5. <https://doi.org/10.1038/s41586-020-2196-x>.
12. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe.* 2020;0(0). [https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3).
13. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med.* 2020;382(16):1564–1567. <https://doi.org/10.1056/NEJMc2004973>.